Pfizer triumphs at environmental awards

Pfizer has been recognised as a leader in environmental excellence at the recent Business Commitment to the Environment (BCE) awards. Twelve companies received recognition...

CORRECTION: MabThera recommended in Scotland

Scottish physicians are now able to prescribe MabThera (rituximab) on the NHS, following a positive recommendation by the Scottish Medicines Consortium (SMC). MabThera was...

GPs need swine flu guidance

A poll of GPs by has revealed that, so far, only 9% of GPs in the UK have been given regular, clear and concise...

Tamiflu discount for poorer countries

Roche is to provide its antiviral Tamiflu at a lower price to developing countries as part of a new initiative. Under the Tamiflu Reserves...

Viruses resistant to Tamiflu identified

Several cases of the H1N1 ‘swine flu’ virus have emerged that are resistant to antiviral drug Tamiflu (oseltaminvir). WHO has been informed by...

Novo Nordisk launches Victoza in UK

Novo Nordisk’s Victoza is now available for type 2 diabetes patients in the UK, following EU approval. Victoza is the first once-daily human Glucagon-like...

Novartis joins fight against malaria

Novartis has become the first healthcare company to join United Against Malaria (UAM), a pan-Africa campaign to end malaria-related deaths and suffering by 2015....

Best-selling drugs cheaper in Europe

European prices of 170 best-selling drugs averaged 40% less than US prices in 2008, recent research has revealed. Within Europe, it was found,...

Study confirms Cervarix efficacy

The largest efficacy trial of a cervical cancer vaccine has shown that Cervarix protects against the five most common cancer-causing virus types. The...

Positive CHMP opinion for Javlor

The CHMP has issued a positive opinion recommending EU marketing authorisation for Javlor from Laboratoires Pierre Fabre. The drug has been recommended for...

Latest articles

Ipad and the cloud: NHSX

NHSX: Combining the best talent from government, the NHS and industry

A new joint unit, NHSX, will be created to bring the benefits of modern technology to every patient and clinician. It will combine the...
Dr Allan Jordan and Ms Louisa Jordison have joined Sygnature Discovery.

Sygnature Discovery makes key appointments

Sygnature Discovery has made two key appointments, Dr Allan Jordan and Ms Louisa Jordison. Ms Jordison joins the independent integrated drug discovery and pre-clinical services...
results published for KEYTRUDA for advanced renal cell carcinoma

KEYTRUDA results published for advanced renal cell carcinoma

MSD has announced presentation of the full results from the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA, MSD’s anti-PD-1 therapy, in combination with Inlyta...